AR Asset Management Inc. Sells 20,000 Shares of Pfizer Inc. (NYSE:PFE)

AR Asset Management Inc. lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,965 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. AR Asset Management Inc.'s holdings in Pfizer were worth $3,581,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter worth $26,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer in the 3rd quarter valued at approximately $35,000. Joseph Group Capital Management raised its position in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 771 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new position in shares of Pfizer during the 4th quarter worth $34,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price target for the company. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim reiterated a "buy" rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Stock Performance

Pfizer stock traded up $0.42 on Friday, hitting $26.32. The company's stock had a trading volume of 54,560,140 shares, compared to its average volume of 38,186,812. The company has a fifty day moving average price of $26.30 and a 200-day moving average price of $27.41. The firm has a market cap of $149.14 billion, a P/E ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date is Friday, January 24th. Pfizer's payout ratio is presently 121.99%.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.